The therapeutic landscape has changed dramatically over the past several years. Treatment options now span substrate reduction and replacement, cofactor replacement, enzyme replacement, RNA-based therapies, cell therapy, gene therapy, and gene editing. The general trend, Whitehead notes, is a movement away from ongoing metabolic replacement strategies such as dietary modification, cofactor supplementation, and enzyme replacement therapy toward single-instance genetic interventions like gene therapy and, eventually, gene editing. To keep pace with this rapidly evolving field, clinicians can consult a dynamic, continuously updated resource known as the Metabolic Treatabolome, which catalogs treatable inherited metabolic disorders. For the practicing radiologist, however, the essential message is simpler: certain reproducible patterns on MRI and MR spectroscopy should trigger immediate consideration of a treatable neurogenetic condition, because these diseases arise from selective tissue vulnerability that produces identifiable and characteristic imaging signatures.

The first challenge is knowing when to suspect a metabolic disorder at all. The imaging characteristics of neurogenetic brain diseases often overlap with far more common entities, particularly hypoxic-ischemic injury and encephalitis. Profound hypoxic-ischemic injury in neonates typically affects the posterior putamen, the posterior limb of the internal capsule, and the ventrolateral thalamus simultaneously, because these regions have high energy demands. When patterns diverge from this expectation, metabolic disease should rise on the differential. Specific red flags include deep gray nuclear lesions that spare the thalami or basal ganglia, temporally disparate lesions, brainstem-predominant abnormalities, unexplained reduction in brain volume, malformations, and chronic lesions in a newborn, none of which fit the typical timeline or distribution of oxygen deprivation or infection.

Among the white matter-dominant disorders, X-linked adrenoleukodystrophy stands out as the single most important diagnosis to know. Caused by variants in the ABCD1 gene, a peroxisomal defect, it is the most common leukodystrophy, it is treatable, and it shows a moderately specific imaging pattern: in roughly 80 percent of cases, demyelination begins in the splenium of the corpus callosum, spreads to the forceps major, descends along projection fibers, and ultimately involves auditory and visual white matter tracts. Active inflammation is marked by reduced diffusivity and contrast enhancement. Alternative phenotypes include frontal onset, deep diffuse, and projectional patterns. With the addition of ABCD1 to the recommended uniform screening panel in the United States, 47 states and the District of Columbia now perform newborn screening, and MRI surveillance identifies the fewer than half of affected boys who develop the cerebral form. Treatment, most effective early when few brain lesions exist, is allogeneic hematopoietic stem cell transplantation, with autologous gene-modified stem cell transplant as a second-line option. Patients with typical lesions and a Loes score below 10 may qualify for therapy, and post-treatment stability is defined as a Loes score below 10 or an increase of less than 6 points from baseline.

Two other leukodystrophies, Krabbe disease and metachromatic leukodystrophy, illustrate how clinical context and subtle imaging distinctions guide diagnosis. Juvenile-onset Krabbe disease can closely mimic X-linked adrenoleukodystrophy with poorly marginated splenial and forceps major abnormality, while the infantile form looks different, featuring lesions in the dentate nuclear hilus, deep cerebral hyperattenuation on CT from galactosylceramide deposition, thalamic T2 shortening, optic chiasm thickening, and enhancement of cranial nerves and the cauda equina. A striated, tigroid pattern in the corona radiata from perivascular myelin sparing is typical but not specific. Hematopoietic stem cell transplant works best before symptoms appear, ideally in the first month of life, which makes newborn screening for GALC enzyme activity, now implemented in 18 states, critically important. Metachromatic leukodystrophy shares several features with infantile Krabbe disease but usually spares the chiasm and hindbrain, may involve the genu earlier, and lacks the deep cerebral hyperattenuation. Markedly elevated myoinositol on spectroscopy and gallbladder disease, even in pre-symptomatic patients, provide additional clues. The preferred treatment is gene therapy using lentivirally modified ARSA, available for children under seven who are pre-symptomatic or only mildly symptomatic, and six states have added MLD to newborn screening panels since its endorsement.

Maple syrup urine disease demonstrates how imaging can track treatment response in real time. This aminoacidopathy typically presents at the end of the first neonatal week with encephalopathy and striking white matter edema, with symmetric, markedly reduced diffusivity and swelling in myelinating and myelinated tracts of the cerebrum, cerebellum, and brainstem. Spectroscopy reveals elevated branched-chain amino acids and ketoacids as a broad doublet near 0.9 to 1 ppm, though detecting these peaks reliably at 3 tesla requires careful echo time selection due to anomalous J-coupling. While protein restriction is necessary and leucine, isoleucine, and valine cannot be eliminated entirely from the diet, liver transplantation is considered a definitive treatment that permits a more relaxed diet. A favorable post-transplant scan shows resolution of the diffusion abnormalities and intramyelinic edema, resolution of lactate, normalization of NAA, and reduction of the branched-chain amino acid peaks, findings documented in a patient imaged seven years after curative transplantation. The mucopolysaccharidoses, a group of multi-system lysosomal storage disorders, offer another treatable example: enlarged perivascular spaces combined with skeletal changes such as a J-shaped sella, frontal bossing, and odontoid hypoplasia suggest the diagnosis, and weekly enzyme replacement therapy has been shown to resolve white matter signal abnormality and stabilize neurological symptoms in eligible patients.

Menkes disease, an X-linked copper transport disorder caused by ATP7A variants, produces one of the most visually distinctive findings in pediatric neuroradiology: diffuse marked elongation and tortuosity of the intracranial arteries, present almost always, even in neonates, because copper is essential for vessel wall integrity. Supporting findings include delayed myelination, transient tumefactive temporal lobe vasogenic edema between one and ten months of life, basal ganglia lesions with reduced diffusion, and skeletal changes such as Wormian bones and fractures. Early daily subcutaneous copper histidinate injections, which bypass the defective copper transporter, are essential for preventing severe neurodegeneration, reducing seizures, and prolonging life. On the gray matter side, Wilson disease from ATP7B variants shows basal ganglia, thalamic, midbrain, and pontine lesions with a characteristic mixed increased-and-decreased signal, where T2 signal correlates with neurological dysfunction and T1 signal with hepatic dysfunction, and the famous face of the giant panda in the midbrain may appear. Copper reduction through diet, zinc supplementation, and chelation, or curative liver transplantation, addresses the underlying metabolic derangement.

Several other gray matter disorders reward pattern recognition. Biotin-thiamine-responsive basal ganglia disease, from SLC19A3 variants, causes thalamic and cortical edema with prominent putaminal involvement, and responds, as its name promises, to lifelong biotin and thiamine supplementation. Glutaric aciduria type 1 announces itself structurally before the basal ganglia lesions appear, with underopercularization and enlarged temporopolar subarachnoid spaces, and early l-carnitine with an arginine-restricted, lysine-free diet is highly effective at preventing permanent striatal injury. Urea cycle defects produce hyperammonemic brain injury with peri-insular and deep cortical lesions that spare the thalami, a pattern unusual in hypoxic-ischemic injury, alongside elevated glutamine and glutamate with reduced myoinositol on spectroscopy; dietary management and, in neonatal-onset ornithine transcarbamylase deficiency, curative liver transplantation are the mainstays. Molybdenum cofactor deficiency type A responds to substrate replacement with cyclic pyranopterin monophosphate, and neuronal ceroid lipofuscinosis CLN2, the most common childhood neurodegenerative disease group, can be slowed by bi-weekly intraventricular cerliponase alfa, identifiable on imaging by cerebellar-predominant atrophy, thalamic T2 shortening, and subinsular signal change.

Finally, MR spectroscopy deserves special emphasis because it can be diagnostic even when the MRI appears entirely normal. Fatty acid metabolism disorders such as CPT1 deficiency produce elevated lipid peaks at 0.9 and 1.3 ppm on a normal-appearing scan, and respond to dietary modification with frequent high-carbohydrate meals and medium-chain fatty acid supplementation. Galactosemia yields a large doublet at 3.7 ppm from toxic galactitol accumulation, which inverts at intermediate echo times and normalizes with dietary change. Cerebral creatine deficiency syndromes show markedly reduced creatine peaks at 3 and 3.95 ppm, and creatine supplementation can normalize the spectrum in AGAT and GAMT deficiency. The review recommends a low threshold for adding short-echo single-voxel spectroscopy to any suspected neurometabolic case, with the voxel placed in the deep gray nuclei for poliodystrophies and parietal white matter for suspected leukodystrophies. The overarching conclusion is unambiguous: symmetric gray or white matter lesions in patterns atypical for hypoxic-ischemic injury and infection, or a characteristic spectroscopic signature, should prompt consideration of these not-to-be-missed disorders, because failure to recognize them promptly delays lifesaving and morbidity-reducing treatment.

Subject of Research: Neuroimaging patterns of treatable neurogenetic and inherited metabolic brain diseases in children

Article Title: Don’t miss this treatable neurogenetic disease!

Article References: Whitehead, M. T. (2026). Don’t miss this treatable neurogenetic disease!. Pediatric Radiology. https://doi.org/10.1007/s00247-026-06796-8

Image Credits: AI Generated

DOI: 10.1007/s00247-026-06796-8

Keywords: neurogenetic diseases, leukodystrophy, MRI, MR spectroscopy, X-linked adrenoleukodystrophy, Krabbe disease, metachromatic leukodystrophy, maple syrup urine disease, Wilson disease, newborn screening, gene therapy, pediatric neuroradiology

Spinal CSF leaks occur when the fluid that cushions the brain and spinal cord escapes through a defect in the dura, the tough membrane that encloses the central nervous system. The loss of fluid leads to intracranial hypotension—abnormally low pressure inside the skull. The hallmark symptom is an orthostatic headache, one that worsens when a child stands upright and eases when they lie down. Valsalva maneuvers such as coughing, sneezing, or bending over can intensify the pain. But the clinical picture is rarely so tidy. Not all children present with positional headaches, and the headaches can fade over time, causing clinicians to overlook the diagnosis entirely. Additional symptoms may include neck pain, muffled hearing, tinnitus, vertigo, and even cranial neuropathies. Because symptoms so often mimic more common conditions, children may spend months or years bouncing between specialists before the leak is identified.

The new review classifies pediatric spinal CSF leaks into two broad categories: nonspontaneous leaks, which follow trauma or medical procedures, and spontaneous leaks, which arise without obvious cause. Nonspontaneous leaks are frequently iatrogenic—the result of a lumbar puncture, an epidural catheter placement, or surgery. A needle puncture most commonly tears the dura dorsally, but if the needle passes all the way through the thecal sac, the resulting tear may be ventral, requiring a very different treatment approach. A lesser-known iatrogenic entity is the arachnoid bleb, in which a small pouch of arachnoid membrane herniates through a dural rent created by a needle. Traumatic leaks, meanwhile, can occur anywhere along the neuroaxis, including the sacrum, and typically appear on MRI as extradural fluid collections.

Spontaneous leaks in children fall into three distinct types: dural tears, CSF-venous fistulas, and CSF-vascular malformation fistulas. Dural tears may be ventral or lateral, and on spine MRI they produce extradural fluid that begins as unorganized collections in acute stages but can evolve into organized, membrane-encased collections in chronic stages as neo-membranes form around the leaked fluid. Notably, the review argues that extradural arachnoid cysts—long considered a separate entity—may actually represent a form of lateral dural tear, with recent research suggesting these lesions are better described on imaging as extradural collections rather than true cysts. One striking case in the review involves an eight-year-old boy with enuresis and constipation whose dorsal thoracolumbar collection remodeled the posterior elements of his vertebrae; digital subtraction myelography pinpointed a contrast jet at the left T12 nerve root, and targeted surgery to repair the dural defect cured him.

CSF-venous fistulas (CVFs) represent an abnormal communication between the subarachnoid space and a spinal vein, allowing CSF to drain directly into the venous system. These are increasingly recognized in adults—indeed, at least one adult study found CVFs more common than dural tears—but they appear to be exceedingly rare in children, where dural tears dominate. The third category, CSF-vascular malformation fistulas, involves unregulated shunting from the spine into a venous or lymphatic malformation, and the review documents a remarkable case in which a fistula first appeared in a sixteen-month-old girl who abruptly stopped walking—initially misdiagnosed as an epidural hematoma—and was only correctly identified twenty-two years later when she presented with headaches and a presumed “Chiari” malformation.

Connective tissue disorders are a significant risk factor in pediatric cases. Marfan syndrome, for instance, can produce dural fragility that predisposes children to spontaneous leaks, often accompanied by sacral dural ectasia visible on imaging. Children with diffuse or paraspinal vascular malformations face elevated risk of CSF-vascular malformation fistulas. The rarity of pediatric leaks overall—spontaneous intracranial hypotension occurs in at least 4 to 5 per 100,000 adults, and less frequently in children—means most clinical knowledge is extrapolated from adult populations, a gap the review aims to help close.

Diagnosis rests on a carefully sequenced imaging algorithm. Contrast brain MRI is the first-line study for suspected intracranial hypotension, with sagittal imaging assessing brain sag and venous distension, pre- and post-gadolinium T1-weighted sequences detecting dural enhancement, and T2 or FLAIR sequences evaluating subdural collections and alternative diagnoses. Optic nerve sheath fluid is another key indicator—when the sheath diameter falls below roughly 4.4 millimeters, an underlying CVF becomes more likely. The SIH Bern score aggregates these findings into a probability assessment: quantitative measurements of the suprasellar cistern (≤4 mm, 2 points), prepontine cistern (≤5 mm, 1 point), and mamillopontine distance (≤6.5 mm, 1 point), combined with qualitative features including dural enhancement (2 points), venous sinus distension (2 points), and subdural collections (1 point), categorize patients as low (0–2), intermediate (3–4), or high (≥5) probability for an underlying leak. Critically, the Bern score was validated only in adults, and the review cautions that its pediatric utility remains unproven.

On spine MRI, the pivotal finding is the spinal longitudinal extradural collection (SLEC)—T2-hyperintense fluid within the epidural space, often spanning multiple levels, best seen on fat-suppressed sequences where it displaces the normally dark epidural fat. The presence or absence of a SLEC determines the downstream pathway. If a SLEC is present, pointing to a dural tear, the patient undergoes CT myelography positioned prone in Trendelenburg for suspected ventral leaks, or in decubitus Trendelenburg for suspected lateral leaks, using small 1–2 milliliter boluses of preservative-free iohexol contrast. A ventral tear appears as a split contrast column extending from the subarachnoid to the ventral epidural space. If no SLEC is seen, decubitus myelography with 5–8 milliliters of contrast searches for CVFs along the entire spine, with the option of rotating the patient to the contralateral side for a bilateral assessment.

The review pays particular attention to pediatric-specific considerations. Ionizing radiation from myelography demands dose minimization—scanning should be concentrated over the SLEC levels rather than repeatedly imaging the whole spine as is sometimes done in adults. Digital subtraction myelography may offer lower radiation exposure than CT myelography while preserving diagnostic accuracy. Contrast dosing must respect age-specific iodine limits, and sedation or general anesthesia is often necessary, requiring careful coordination with anesthesia teams regarding prone and Trendelenburg positioning. A particularly instructive pitfall is the confusion between intracranial hypotension and Chiari 1 deformity: both can cause cerebellar tonsillar descent, and Chiari 1 can even develop during childhood as the skeleton grows, mimicking acquired brain sag. The mamillopontine distance is the decisive discriminator—reduced in intracranial hypotension, preserved in Chiari 1.

Treatment options span three approaches. Epidural blood patching, performed under CT or fluoroscopic guidance, delivers autologous blood to the dural defect; for ventral tears, needles are advanced through the lower third of the neural foramen to avoid the vasculature and nerves in the upper third. The review emphasizes that the traditional 20-milliliter blood volume, drawn from obstetric literature, should not be treated as a fixed requirement—patching volume should be individualized to leak location, patient size, and imaging appearance. Fibrin glue, though off-label, offers stronger adhesive sealing properties and can be used alone or with blood. For CVFs, targeted fibrin glue patching at the cyst-vein junction or transvenous embolization—selectively catheterizing the involved vein and injecting embolic material—are both viable, though no direct comparisons exist. Surgery remains the definitive option for any leak type, particularly ventral dural tears with organized collections and arachnoid blebs that resist patching.

Perhaps the review’s most clinically valuable contribution is its guidance on patients with negative MRI findings. In children, unlike adults, most true CSF leaks will show abnormalities on brain MRI, spine MRI, or both; definitive CVFs with entirely normal imaging are the exception. When initial MRIs are normal and suspicion is low to intermediate, the review advises careful re-review of subtle findings like venous distension before considering myelography or empiric patching—and stresses that unnecessary invasive procedures in children should be minimized. With modern myelography, image-guided patching, and endovascular therapies now mature, the neuroradiologist has moved from a purely diagnostic role to the center of both detection and cure for this hidden epidemic of childhood headache.